Direkt zum Inhalt
Merck
  • High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cells.

High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cells.

Journal of biomolecular screening (2010-07-14)
Sashi Nadanaciva, Keith Dillman, David F Gebhard, Alka Shrikhande, Yvonne Will
ZUSAMMENFASSUNG

Compounds that interfere with the synthesis of either mitochondrial DNA or mtDNA-encoded proteins reduce the levels of 13 proteins essential for oxidative phosphorylation, leading to a decrease in mitochondrial adenosine triphosphate (ATP) production. Toxicity caused by these compounds is seldom identified in 24- to 72-h cytotoxicity assays due to the low turnover rates of both mtDNA and mtDNA-encoded proteins. To address this problem, the authors developed a 96-well format, high-content screening (HCS) assay that measures, in eukaryotic cells, the level of Complex IV-subunit 1, an mtDNA-encoded protein synthesized on mitochondrial ribosomes, and the level of Complex V-alpha subunit, a nuclear DNA-encoded protein synthesized on cytosolic ribosomes. The effect of several antibiotics and antiretrovirals on these 2 proteins was assessed, in transformed human liver epithelial cells, 6 days after compound treatment. The results confirmed effects of drugs known to reduce mtDNA-encoded protein levels and also revealed novel information showing that several fluoroquinolones and a macrolide, josamycin, impaired expression of mtDNA-encoded proteins. The HCS assay was robust with an average Z' factor of 0.62. The assay enables large-scale screening of compounds to identify those that potentially affect mtDNA-encoded protein levels and can be implemented within a screening paradigm to minimize compound attrition.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Josamycin, ≥90% (HPLC)
Josamycin, European Pharmacopoeia (EP) Reference Standard